Posts tagged ESPR


Wall Street Cheers These Two Rising Stocks: Esperion Therapeutics Inc (ESPR) and Nektar Therapeutics (NKTR)

Esperion Therapeutics Inc (NASDAQ:ESPR) and Nektar Therapeutics (NASDAQ:NKTR) are skyrocketing with a fury today on …

Read more

Stock Update (NASDAQ:ESPR): Esperion Therapeutics Inc Announces Initiation of Global Cardiovascular Outcomes Trial in Bempedoic Acid

Esperion Therapeutics Inc (NASDAQ:ESPR) announced the initiation of the global cardiovascular outcomes trial (CVOT) to …

Read more

Chardan Analyst Cautious on Esperion Therapeutics Inc’s (ESPR) Phase II PK/PD Study Results

In a research report released Thursday, Chardan Capital analyst Gbola Amusa reiterated a Neutral rating on …

Read more

Stock Update (NASDAQ:ESPR): Esperion Therapeutics Inc Provides Clinical Update for Bempedoic Acid Phase 3 Clinical Program

Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced the bempedoic acid global pivotal Phase 3 LDL-C lowering clinical development …

Read more

Wednesday Morning’s Biotech Insights: Galena Biopharma Inc (GALE), Esperion Therapeutics Inc (ESPR), Lipocine Inc (LPCN)

Galena Biopharma Inc (NASDAQ:GALE) is plummeting 80% in early morning trading after the company discontinued …

Read more

Company Update (NASDAQ:ESPR): Esperion Therapeutics Inc Provides Clinical Development and Regulatory Update for Bempedoic Acid

Esperion Therapeutics Inc (NASDAQ:ESPR), a late-stage pharmaceutical company focused on developing and commercializing first-in-class oral therapies …

Read more

Company Update (NASDAQ:ESPR): Esperion Therapeutics Inc Reports First Quarter 2016 Financial Results

Esperion Therapeutics Inc (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein …

Read more

Stock Update (NASDAQ:ESPR): Esperion Therapeutics Inc Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study

Esperion Therapeutics Inc (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein …

Read more

Stock Update (NASDAQ:ESPR): Esperion Therapeutics Inc Provides ETC-1002 Development Program Update; Reports Third Quarter 2015 Financial Results

Esperion Therapeutics Inc (NASDAQ:ESPR), a pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density …

Read more

Biotech Beat: Sarepta Therapeutics Inc (SRPT), Esperion Therapeutics Inc (ESPR), Valeant Pharmaceuticals Intl Inc (VRX)

By Terry Chrisomalis Sarepta Therapeutics Inc On October 1, 2015 shares of Sarepta Therapeutics Inc …

Read more